Unknown PHASE3 INTERVENTIONAL NCT00426049

Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease

Sponsor: German Heart Institute

Conditions Coronary Artery Disease Coronary Restenosis

Interventions Everolimus

Updated 4 times since 2017 Last updated: Jan 23, 2007 Started: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Coronary Artery Disease and Coronary Restenosis, this trial is ongoing. The trial is conducted by German Heart Institute and has accumulated 4 data snapshots since 2006. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

German Heart Institute
Novartis

Data source: German Heart Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany